Gevokizumab

Gevokizumab is a currently still experimental, recombinant, highly potent anti-IL-1β antibody that has so far been researched primarily in inflammatory diseases. Gevokizumab negatively modulates IL-1β signaling through an allosteric mechanism. The antibody selectively reduces the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI).

Study results on Behçet's disease (Tugal-Tutkun I et al. 2018) on type 1 and 2 diabetes and on the autoinflammatory diseases "Familial cold autoinflammatory syndrome" and "Muckle-Wells syndrome" have not yet led to approval (Promelle V et al. 2021).

Interleukin-1β (IL-1β) is an important immunomodulatory cytokine involved in all steps of carcinogenesis, including tumor growth, invasion, angiogenesis, immune cell function and tumor microenvironment composition.

1. Geiler J et al. (2010) Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther 12:755-769.
2. Promelle V et al. (2021) Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives. J Clin Med 10):2118.
3. Rattray C et al. (2024) Felty Syndrome in a Patient Presenting With Bilateral Scleritis and Multiple Autoimmune Syndrome: A Case Report. Cureus 16:e57468.
4. Tugal-Tutkun I et al. (2018) Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocul Immunol Inflamm 26: 1023-1033.